Cargando…

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia

Detalles Bibliográficos
Autores principales:	Lode, H, Choudhri, S, Haverstock, D, Jackson, P, Church, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2002
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333751/ http://dx.doi.org/10.1186/cc1792

Ejemplares similares

Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study
por: Schaper, N. C., et al.
Publicado: (2012)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
por: Kuzman, Ilija, et al.
Publicado: (2014)

A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Ferrara, Anna M
Publicado: (2007)

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS
por: Rahmel, Tim, et al.
Publicado: (2017)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy
por: Zhou, Bo, et al.
Publicado: (2020)

Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
por: Du, Xiwen, et al.
Publicado: (2021)

Severe community acquired pneumonia and ARDS: prognostic factors in infants
por: Chidini, G, et al.
Publicado: (2003)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results
por: Wilson, Robert, et al.
Publicado: (2012)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Update on the Cardiac Safety of Moxifloxacin
por: Haverkamp, Wilhelm, et al.
Publicado: (2012)

Heterogeneous penetration of cefpirome and moxifloxacin into abscesses after simultaneous administration in humans
por: Sauermann, Robert, et al.
Publicado: (2010)

Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin
por: Sugioka, Koji, et al.
Publicado: (2009)

A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia
por: Tokimatsu, Issei, et al.
Publicado: (2017)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia
por: Zhao, Bo, et al.
Publicado: (2020)

Moxifloxacin modulates inflammation during murine pneumonia
por: Beisswenger, Christoph, et al.
Publicado: (2014)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

Correlation between plasma peroxides and procalcitonin levels in patients with severe streptococcal community acquired pneumonia
por: Borrelli, E, et al.
Publicado: (2002)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

Initial plasma levels of lipopolysaccharide binding protein are associated with severe sepsis in patients with community-acquired pneumonia
por: Martino, ML, et al.
Publicado: (2003)

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
por: Tanaseanu, Cristina, et al.
Publicado: (2009)

Diagnostic performance of chest X-ray for the diagnosis of community acquired pneumonia in acute admitted patients with respiratory symptoms
por: Laursen, Christian B, et al.
Publicado: (2013)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Severe community acquired adenovirus pneumonia in an immunocompetent host successfully treated with IV Cidofovir
por: Zhao, Joseph, et al.
Publicado: (2020)

Moxifloxacin Safety: An Analysis of 14 Years of Clinical Data
por: Tulkens, Paul M., et al.
Publicado: (2012)

Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children
por: Alsuhaibani, Mohammed, et al.
Publicado: (2019)

663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials
por: Shorr, Andrew F, et al.
Publicado: (2019)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

COMMUNITY-ACQUIRED PNEUMONIA
por: Haas, Andrew R., et al.
Publicado: (2009)

Community-acquired pneumonia
por: File, Thomas M
Publicado: (2003)

Community-Acquired Pneumonia
por: Sialer, Salvador, et al.
Publicado: (2014)

Community Acquired Pneumonia
por: Wunderink, Richard G., et al.
Publicado: (2016)

Community-Acquired Pneumonia
por: Boza Costagliola, María Lina
Publicado: (2020)

Community Acquired Pneumonia
por: Wunderink, Richard G.
Publicado: (2019)

Community-Acquired Pneumonia
por: Rider, Ashley C., et al.
Publicado: (2018)

Community-acquired pneumonia
por: Niederman, Michael S.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2ob71hqu5e5se307rf48l7dcc7